Beta-blockers in patients with cirrhosis and refractory ascites

Hepatology

Volumn 53, Issue 5, 2011, Pages 1783-

  Agustín, Albillos ^a,c   Javier, Zamora ^b,c,d  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ASCITES; DRUG EFFECT; HUMAN; LETTER; LIVER CIRRHOSIS; MORTALITY; PRIORITY JOURNAL;

EID: 79955116369     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24032     Document Type: Letter

References (5)

1. Serstè T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. HEPATOLOGY 2010; 52: 1017-1022.
2. Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? HEPATOLOGY 2010; 52: 811-813.
3. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer 2003; 89: 781-786.
4. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: John Wiley & Sons; 1999: 248-253.
5. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.